Description
Key facts
Cell type:A549,
Species or organism:Human,
Tissue:Lung,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 201 bp deletion in exon5.,
Disease:Carcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-ETV7, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The ETV7 also known as TEL2 is a member of the ETS family of transcription factors with a molecular weight of approximately 53 kDa. This protein localizes predominantly in the nucleus and influences gene expression regulation. ETV7 is expressed in a variety of tissues with notable expression levels in hematopoietic cells. Its role extends to modulating different genes critical for cellular proliferation and differentiation.
Biological function summary
ETV7 acts as a transcriptional repressor and influences immune responses and cell cycle regulation. This protein functions as part of larger transcriptional complexes interacting with other cofactors to modulate gene expression. ETV7 influences hematopoiesis impacting both the development and function of blood cells by repressing certain cytokine receptors and transcription factors tightly controlling the cellular environment.
Pathways
ETV7 plays an integral role in pathways related to hematopoiesis and immune cell regulation. It participates in the JAK-STAT signaling pathway collaborating with proteins such as STAT5 to regulate immune responses and cell proliferation. Additionally ETV7 is involved in the regulation of cytokine signaling pathways impacting cellular growth and immune system balance.
ETV7 holds significance in the development of certain cancers particularly hematological malignancies. It has associations with acute myeloid leukemia (AML) where its overexpression contributes to leukemogenesis alongside proteins like FLT3. ETV7 also plays a role in B-cell chronic lymphocytic leukemia (CLL) affecting the balance of pro-survival and apoptotic mechanisms further linking its activity with the tumor suppressor protein TP53. Understanding ETV7's interactions helps to illuminate its potential as a therapeutic target in these conditions.
